Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these “HER2-low” cancers.
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy
FCS hematologist and medical oncologist James Reeves, Jr., MD co-authored a recently published study evaluating the monarchE randomized clinical trial. Findings of the study demonstrated benefits from treatment with adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, ERBB2−, node-positive, and high-risk early breast cancer who received neoadjuvant chemotherapy before trial enrollment.
A Prespecified Analysis of the monarchE Randomized Clinical Trial
Patients selected to receive neoadjuvant chemotherapy (NAC) are usually those at higher risk of relapse, and there is a need to find better therapeutic options for these patients.
To determine the efficacy and safety outcomes for patients with hormone receptor (HR)–positive, ERBB2 (formerly HER2)–, high-risk early breast cancer enrolled in the randomized clinical trial monarchE who received NAC.
DESIGN, SETTING, AND PARTICIPANTS
The monarchE randomized clinical trial was a multicenter, phase 3, open-label study that evaluated adjuvant treatment with abemaciclib plus endocrine therapy (ET) compared with ET alone in patients with HR+, ERBB2–, and node-positive early breast cancer who were at high risk of recurrence. Patients were recruited between July 2017 and August 2019 from 603 sites in 38 countries. This subgroup analysis was performed with primary outcome data, with a cutoff date of July 8, 2020.
Enrolled patients were randomized (1:1) to receive standard of care ET for at least 5 years with or without treatment with abemaciclib (150 mg, twice daily) for 2 years (treatment period) or until criteria were met for discontinuation.
MAIN OUTCOMES AND MEASURES
Prior chemotherapy (NAC vs adjuvant vs none) was a stratification factor in monarchE, and and a prespecified exploratory analysis included outcomes in patients who received NAC. The data presented in this article are from the primary outcome analysis (395 invasive disease-free survival [IDFS] events; cutoff date, July 8, 2020; median follow-up 19 months [IQR, 15.6-23.9 months]). Invasive disease-free survival (the primary end point of monarchE) and distant relapse-free survival (DRFS) were evaluated using the Cox proportional hazard model and Kaplan-Meier method.
Of the 5637 patients (mean [SD] age, 49.9 [10.6] years; 2046 women [99.5%]; 462 Asian [22.8%], 54 Black [2.7%], and 1473 White participants [70.8%]) enrolled in monarchE, 2056 (37%) received treatment with NAC. In this subgroup, treatment with abemaciclib and ET demonstrated clinically meaningful benefit in IDFS (hazard ratio, 0.61; 95% CI, 0.47-0.80) and DRFS (hazard ratio, 0.61; 95% CI, 0.46-0.81), which corresponded with an absolute improvement of 6.6% in 2-year IDFS rates and 6.7% in 2-year DRFS rates. A consistent treatment benefit was observed across subgroups of pathological breast tumor size or number of positive lymph nodes at surgery.
CONCLUSIONS AND RELEVANCE
In the randomized clinical trial monarchE, treatment with adjuvant abemaciclib combined with ET demonstrated a clinically meaningful improvement in IDFS and DRFS for patients with HR+, ERBB2−, node-positive, high-risk early breast cancer who received NAC before trial enrollment.
ClinicalTrials.gov Identifier: NCT03155997
Author Affiliations1Medical Oncology Service, Hospital General Universitario Gregorio Marañon, Universidad Complutense, Centro de Investigación Biomédica en Red-Cáncer, Grupo Español de Investigación en Cáncer de Mama, Madrid, Spain 2Clinica de Pesquisa e Centro São Paulo, São Paulo, Brazil 3Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 4Centrul de Oncologie Sf Nectarie SRL, University of Medicine and Pharmacy Craiova, Craiova, Romania 5Institutul Oncologic “Prof.Dr. Ion Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania 6Medical Oncology Service, Hospital Clinico San Carlos, GEICAM, Madrid, Spain 7Euromedica, General Clinic of Thessaloniki, Thessaloniki, Greece 8Hunan Cancer Hospital, Changsha, China 9Dolnoslaskie Centrum Onkologii, Uniwersytet Medyczny we Wroclawiu, Wroclaw, Poland 10Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey 11Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers 12Adelaide Cancer Centre, Kurralta Park, Australia 13Instituto D’Or de Pesquisa e Ensino, São Paulo, Brazil 14National Center for Global Health and Medicine, Tokyo, Japan 15Virginia Cancer Specialists, US Oncology Network, Arlington, Virginia 16Communal Enterprise “Kryvyi Rih oncology dispensary” Dnipr region, Kryvyi Rih, Ukraine 17Cancer Center of Kansas, Wichita, Kansas 18Eli Lilly and Company, Indianapolis, Indiana 19Royal Marsden National Health Service Foundation Trust, London, England
Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer
Patients who are uninsured and belong to racial and ethnic minority groups or have low socioeconomic status have suboptimal access to health care, likely affecting outcomes.
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a taxane.
In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer.
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline.